The Washington DC region is part of an east coast corridor rich in life science talent, technical know-how and business development expertise. Montgomery County, Maryland itself is host to a unique ecosystem of potential resources for startups in health tech: centers of research, strong universities, leading biotech and pharma companies, and government agencies. This ecosystem means that health tech founders can immediately access resources and build the strategic partnerships to support their rapid growth.
This event will discuss Relevant Health, a new health tech startup accelerator program based in Rockville, Maryland, and the regional environment for startups in health tech. Come ready both to hear about opportunities for startups and discuss your experiences and needs as someone interested in building our health tech capital.
Relevant Health, a newly launched innovative health technology startup accelerator focused on bringing products to market, announced that it is now accepting applications from health tech startups for its Fall 2015 class. Additionally, the accelerator launched its website and the portal to its streamlined application process. U.S. and international startups are encouraged to apply.
Relevant Health’s five-month program involves an intensive product-focused curriculum that gives founders of health tech startups the skills to define, develop, position and launch a viable health tech product. The new accelerator will be based out of a brand-new cowork space in the Rockville Innovation Center, centrally located in the heart of the Montgomery County (Maryland) life sciences corridor. Companies admitted to the accelerator will have access to the cowork facility along with other support that includes up to $50,000 in funding, mentorship, development support from a pool of software engineers, and access to the local health tech ecosystem.
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it is launching a ruggedized, military-grade auto-injector device, known as Emergard™, which is designed for intramuscular self-injection of antidotes and other emergency response medical treatments that can address exposure to certain chemical agents and other similar emerging threats. Emergard is not approved by the U.S. Food and Drug Administration (FDA) and is not currently marketed in the U.S., although the company intends to pursue FDA approval of the device. The company has received preliminary interest for Emergard from countries outside the U.S. and anticipates making its first deliveries in limited quantities in Q4 2015.
Tom Sadowski, president and CEO of the Economic Alliance of Greater Baltimore, joins the Baltimore Metropolitan Council (BMC) Board of Directors as a representative appointed by Governor Larry Hogan.
“It is imperative that our planning efforts complement economic development activity as we work to promote prosperity in the Baltimore region,” said Michael B. Kelly, executive director of the Baltimore Metropolitan Council. “In Tom Sadowski, BMC’s Board of Directors gains a wealth of knowledge and experience – especially in fostering and maintaining regional partnerships and promoting positive economic development initiatives. We look forward to working with him.”
Chevy Chase-based New Enterprise Associates ranked among the VC firms with the best exits (meaning biggest acquisitions and initial public offerings) between 2009 and 2015, according to a new report from CB Insights.
Silicon Valley firms Sequoia Capital and Accel Partners were also included at the top of the list.
A gel being developed in the lab at Johns Hopkins University is designed to make all signs of wounds disappear.
Gemstone Biotherapeutics, which focuses on wound care, grew out of the research of Hopkins engineering professor Sharon Gerecht. The winner of Hopkins’ first-ever President’s Frontier Award, Gerecht’s work is focused on tissue repair.
GenArraytion, Inc., is pleased to announce a manufacturing license agreement with Chemring Detection Systems, Inc. (“CDS”), a subsidiary of Chemring Sensors & Electronic Systems (CSES) and part of Chemring Group PLC (“Chemring”), in support of the development of the Commercial-Off-the-Shelf (COTS) Athina Consumable Cartridge product. GenArraytion will provide a highly multiplexed molecular assay panel on Luminex magnetic beads that will detect multiple biological warfare agents in a single reaction as part of the Athina Consumable Cartridge solution.
CDS was awarded a $14,934,533 cost-plus-incentive-fee incrementally funded JBTDS contract with options last month. The Athina product technology is the basis for the awarded JBTDS solution. Fiscal year 2015 research, development, testing and evaluation funds in the amount of $4,456,639 were obligated at the time of the award. CSES was granted the contract after an evaluation and selection process that began in early 2014.
Newt Fowler, a longtime advisor and business planner for Baltimore entrepreneurs and investors, has been named chair of the Maryland Technology Development Corp.
Fowler, a business transactions partner with Baltimore’s Womble Carlyle LLP, is among four officers elected by the 15-member board of directors.
Silver Spring-based United Therapeutics’ quarterly sales got a boost from its newest treatment for pulmonary arterial hypertension, while higher research and development costs, and a bigger payroll, dragged down the bottom line.
United Therapeutics had second quarter revenue of $347.2 million, up 7.5 percent from $322.8 million in revenue in the same quarter a year earlier. Net income was $99.2 million, or $1.91 per share, compared to net income of $111.9 million, or $2.10 per share a year ago.
The term ‘translational sciences’ means different things to different people. For MedImmune, the global biologics research and development arm of AstraZeneca, the term refers to our expertise in accelerating drug development through the careful selection of the right patients in early clinical trials. As recently shared by Dr. Bahija Jallal, Executive Vice President, AstraZenenca, and Head of MedImmune at the recent ‘ON Helix’ translational research conference hosted by One Nucleus, translational science is a mind-set that’s embedded throughout MedImmune.
The federal government is attempting to ensure that doctors don’t inadvertently compromise patient data when they use smartphones to access electronic health records.
The National Institutes of Standards in Technology this week released a step-by-step guide for hospitals and IT professionals, listing ways to secure the connection between devices and electronic health records.
Maryland Technology Development Corp.’s new board chair, Newt Fowler, is stepping in as the investment agency’s responsibility grows five-fold.
TEDCO this year will take over disparate investment programs from Maryland’s Department of Business and Economic Development, most notably the state’s Maryland Venture Fund. All told, the shift will put an additional $100 million under TEDCO’s management beginning Oct. 1.
A recent Kauffman Foundation study found that year-over-year startup activity in the U.S. increased in 2015 for the first time in five years and showed the largest increase in more than 20 years. This is particularly good news from an employment perspective because new firms create the vast majority of net new jobs. And, fortunately for the Greater Baltimore market, Maryland is recognized as a leader in innovation. When compared to other Northeast Corridor metros, Greater Baltimore has historically had a greater startup rate than Boston and Philadelphia.
The Pentagon today awarded its years-in-the-making multibillion contract to upgrade its electronic health records system, to defense IT firm Leidos, which partnered with electronic health record vendor Cerner and Accenture Federal.
The Defense Healthcare Management Systems Modernization contract’s base value is $4.3 billion over 10 years, with an expected 18-year lifecycle value of $9 billion, and will put Leidos in charge of building a next-generation health records system responsible for DOD’s 9.6 million beneficiaries.
Three American universities are set to conduct wide-ranging research on cryptocurrencies using roughly $3m in grant funding from the National Science Foundation, a US government agency that supports and funds scientific research.
Cornell, the University of Maryland and the University of California Berkeley will focus on developing new cryptocurrency systems that, according to principal investigator Elaine Shi, will address “pain points” attributed to bitcoin and other existing networks.
Three venture firms stand out in a new study by CB Insight of who consistently enjoyed the biggest exits — IPOs or sales — of their portfolio companies.
Sequoia Capital, Accel Partners and New Enterprise Associates had at least five of the top exits in two windows used in the study. They were the only ones to be in the top five for both periods used in the CB Insights research.
The world population is continuing to grow for various reasons, and it’s growing fast.
A recent report released by the United Nations revealed that the current world population is 7.3 billion, is expected to reach 8.5 billion by 2030, 9.7 billion in 2050 and 11.2 billion in 2100.
Today Startup Maryland announced updates to the schedule (September 12 – October 2) and the rough route for the Pitch Across Maryland, the fourth annual state-wide tour and celebration of entrepreneurship and high-growth startup companies.
The Pitch Across Maryland tour will again traverse the state all in the name of celebrating Maryland’s diverse communities of venture building. A sampling of details, key data and results from previous tours follow:
Developing lab research into the foundations of a profitable biotech company has always been a high-risk, high-reward business.
Deerfield Management, a New York-based healthcare investor with more than $5 billion under management and two decades of experience, has created a new $550 million fund that targets early stage science from academic medical centers and hospitals. The fund is specifically focused on innovative treatments for genetic disorders, cancer, and orphan diseases.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
